Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.72 |
| ▸ | NPC1 | O15118 | 11/20 | 0.72 |
| ▸ | MAPT | P10636 | 10/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | PKM | P14618 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16701199 | 1.00 | RAB9A (0.72) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL16698155 | 0.81 | RAB9A (0.61) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL16698157 | 0.81 | RAB9A (0.61) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14027380 | 0.80 | RAB9A (0.76) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL16701197 | 0.78 | NPC1 (0.49) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL16697642 | 0.78 | RAB9A (0.62) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL16697639 | 0.78 | RAB9A (0.62) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL14027376 | 0.77 | RAB9A (0.77) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL16697855 | 0.73 | RAB9A (0.59) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL16697859 | 0.73 | RAB9A (0.59) | RAB9ANPC1MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | VIROCURA THERAPEUTICS INC (CA) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133495-A1 | Substituted Acyloxyamidines as HCV NS3/4A Inhibitors | EIF2AK2, GTF3C4, GTF3C1 | RAB9A 465/4885NPC1 922/4885MAPT 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.